用巴利昔单抗治疗类固醇抵抗性急性肝移植排斥反应。
Treatment of steroid-resistant acute liver transplant rejection with basiliximab.
作者信息
Fernandes M L, Lee Y M, Sutedja D, Wai C T, Isacc J, Prabhakaran K, Lim S G, Lee K H
机构信息
Liver Transplant Unit, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074.
出版信息
Transplant Proc. 2005 Jun;37(5):2179-80. doi: 10.1016/j.transproceed.2005.03.030.
Current rescue therapies for acute steroid-resistant rejection, such as OKT3 and high-dose tacrolimus, are not uncommonly associated with side effects that contribute to significant morbidity of the patient. Basiliximab is a chimeric monoclonal antibody that acts as an interleukin-2 receptor antagonist on the surface of activated T lymphocytes. It has until now only been used as immunoprophylaxis in adult liver transplant patients. In this report, we describe the use of Basiliximab as rescue therapy in a case of acute steroid-resistant rejection in an adult living related liver transplant recipient.
目前用于急性类固醇抵抗性排斥反应的挽救疗法，如OKT3和高剂量他克莫司，常常伴有导致患者出现严重并发症的副作用。巴利昔单抗是一种嵌合单克隆抗体，可作为活化T淋巴细胞表面的白细胞介素-2受体拮抗剂。到目前为止，它仅在成人肝移植患者中用作免疫预防。在本报告中，我们描述了在一例成人活体亲属肝移植受者发生急性类固醇抵抗性排斥反应时，使用巴利昔单抗作为挽救疗法的情况。
Zotero 插件